Mitochondrial Dysfunction in Alzheimer's Disease: a Key Frontier for Future Targeted Therapies

Overview

Journal Front Immunol

Date 2025 Jan 29

PMID 39877373

Authors

Shuguang Wang

Zuning Liao

Qiying Zhang

Xinyuan Han

Changqing Liu

Jin Wang

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disorder, accounting for approximately 70% of dementia cases worldwide. Patients gradually exhibit cognitive decline, such as memory loss, aphasia, and changes in personality and behavior. Research has shown that mitochondrial dysfunction plays a critical role in the onset and progression of AD. Mitochondrial dysfunction primarily leads to increased oxidative stress, imbalances in mitochondrial dynamics, impaired mitophagy, and mitochondrial genome abnormalities. These mitochondrial abnormalities are closely associated with amyloid-beta and tau protein pathology, collectively accelerating the neurodegenerative process. This review summarizes the role of mitochondria in the development of AD, the latest research progress, and explores the potential of mitochondria-targeted therapeutic strategies for AD. Targeting mitochondria-related pathways may significantly improve the quality of life for AD patients in the future.

References

Ma Q, Xing C, Long W, Wang H, Liu Q, Wang R . Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis. J Neuroinflammation. 2019; 16(1):53. PMC: 6397457. DOI: 10.1186/s12974-019-1434-3. View

Canugovi C, Shamanna R, Croteau D, Bohr V . Base excision DNA repair levels in mitochondrial lysates of Alzheimer's disease. Neurobiol Aging. 2014; 35(6):1293-300. PMC: 5576885. DOI: 10.1016/j.neurobiolaging.2014.01.004. View

Soltys D, Pereira C, Rowies F, Farfel J, Grinberg L, Suemoto C . Lower mitochondrial DNA content but not increased mutagenesis associates with decreased base excision repair activity in brains of AD subjects. Neurobiol Aging. 2018; 73:161-170. DOI: 10.1016/j.neurobiolaging.2018.09.015. View

Sun Y, Sommerville N, Liu J, Ngan M, Poon D, Ponomarev E . Intra-gastrointestinal amyloid-β1-42 oligomers perturb enteric function and induce Alzheimer's disease pathology. J Physiol. 2020; 598(19):4209-4223. PMC: 7586845. DOI: 10.1113/JP279919. View

Calvo-Rodriguez M, Bacskai B . Mitochondria and Calcium in Alzheimer's Disease: From Cell Signaling to Neuronal Cell Death. Trends Neurosci. 2020; 44(2):136-151. DOI: 10.1016/j.tins.2020.10.004. View

Manczak M, Kandimalla R, Fry D, Sesaki H, Reddy P . Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease. Hum Mol Genet. 2016; 25(23):5148-5166. PMC: 6078633. DOI: 10.1093/hmg/ddw330. View

Eckert A, Schulz K, Rhein V, Gotz J . Convergence of amyloid-beta and tau pathologies on mitochondria in vivo. Mol Neurobiol. 2010; 41(2-3):107-14. PMC: 2876263. DOI: 10.1007/s12035-010-8109-5. View

Shao C, Xiong S, Li G, Gu L, Mao G, Markesbery W . Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain. Free Radic Biol Med. 2008; 45(6):813-9. PMC: 2745061. DOI: 10.1016/j.freeradbiomed.2008.06.003. View

DSouza A, Minczuk M . Mitochondrial transcription and translation: overview. Essays Biochem. 2018; 62(3):309-320. PMC: 6056719. DOI: 10.1042/EBC20170102. View

10.

Zhang H, Zhu Y, Suehiro Y, Mitani S, Xue D . AMPK-FOXO-IP3R signaling pathway mediates neurological and developmental defects caused by mitochondrial DNA mutations. Proc Natl Acad Sci U S A. 2023; 120(36):e2302490120. PMC: 10483642. DOI: 10.1073/pnas.2302490120. View

11.

Ionescu-Tucker A, Cotman C . Emerging roles of oxidative stress in brain aging and Alzheimer's disease. Neurobiol Aging. 2021; 107:86-95. DOI: 10.1016/j.neurobiolaging.2021.07.014. View

12.

Adav S, Park J, Sze S . Quantitative profiling brain proteomes revealed mitochondrial dysfunction in Alzheimer's disease. Mol Brain. 2019; 12(1):8. PMC: 6350377. DOI: 10.1186/s13041-019-0430-y. View

13.

Limanaqi F, Biagioni F, Gambardella S, Familiari P, Frati A, Fornai F . Promiscuous Roles of Autophagy and Proteasome in Neurodegenerative Proteinopathies. Int J Mol Sci. 2020; 21(8). PMC: 7215558. DOI: 10.3390/ijms21083028. View

14.

Shields L, Kim H, Zhu L, Haddad D, Berthet A, Pathak D . Dynamin-related protein 1 is required for normal mitochondrial bioenergetic and synaptic function in CA1 hippocampal neurons. Cell Death Dis. 2015; 6:e1725. PMC: 4650558. DOI: 10.1038/cddis.2015.94. View

15.

Stoccoro A, Siciliano G, Migliore L, Coppede F . Decreased Methylation of the Mitochondrial D-Loop Region in Late-Onset Alzheimer's Disease. J Alzheimers Dis. 2017; 59(2):559-564. DOI: 10.3233/JAD-170139. View

16.

Mary A, Eysert F, Checler F, Chami M . Mitophagy in Alzheimer's disease: Molecular defects and therapeutic approaches. Mol Psychiatry. 2022; 28(1):202-216. DOI: 10.1038/s41380-022-01631-6. View

17.

Yang A, Bagit A, MacPherson R . Resveratrol, Metabolic Dysregulation, and Alzheimer's Disease: Considerations for Neurogenerative Disease. Int J Mol Sci. 2021; 22(9). PMC: 8125227. DOI: 10.3390/ijms22094628. View

18.

Lopez-Lee C, Torres E, Carling G, Gan L . Mechanisms of sex differences in Alzheimer's disease. Neuron. 2024; 112(8):1208-1221. PMC: 11076015. DOI: 10.1016/j.neuron.2024.01.024. View

19.

Pradeepkiran J, Reddy P . Defective mitophagy in Alzheimer's disease. Ageing Res Rev. 2020; 64:101191. PMC: 7710581. DOI: 10.1016/j.arr.2020.101191. View

20.

Payne A, Nahashon S, Taka E, Adinew G, Soliman K . Epigallocatechin-3-Gallate (EGCG): New Therapeutic Perspectives for Neuroprotection, Aging, and Neuroinflammation for the Modern Age. Biomolecules. 2022; 12(3). PMC: 8945730. DOI: 10.3390/biom12030371. View